Bahija Jallal, PhD
Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Prior to joining Immunocore in January 2019, she was president of MedImmune, AstraZeneca’s global biologics research and development unit. She was also executive vice president of AstraZeneca and a member of its senior executive team. Bahija serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation. Bahija has authored more than 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. She is also the immediate past president of the Association of Women in Science. Bahija was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.
Prior to joining MedImmune, Bahija was vice president, drug assessment and development, at Chiron Corporation, where she successfully established the company’s translational medicine group. Prior to Chiron Corporation, she was part of the research team at Sugen, Inc. Bahija received her PhD in Physiology from Université de Paris VI, France and conducted her post-doctorate work in molecular biology and oncology at the Max Planck Institute for Biochemistry in Germany.
Year appointed: 2019